PMID- 35450220
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1664-8021 (Print)
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 13
DP  - 2022
TI  - The Role of RNA-Binding Protein HuR in Lung Cancer by RNA Sequencing Analysis.
PG  - 813268
LID - 10.3389/fgene.2022.813268 [doi]
LID - 813268
AB  - Background: The overexpression of human antigen R (HuR) has been proven in 
      various types of cancer and is associated with the poor survival lung cancer 
      patients. HuR overexpression stabilizes the mRNA of tumor-promoting genes by 
      binding with 3'-UTR AU-rich elements. However, the role of HuR in the 
      proliferation of lung cancer is unclear. Methods: HuR expression was assessed 
      using immunohistochemistry of tumor tissue samples from ten patients with lung 
      cancer and ten patients with benign lung disease. Gene, protein, mRNA, and lncRNA 
      changes in A549 HuR knockdown (KD) cells were assessed by single-cell RNA 
      sequencing analysis. Furthermore, cell proliferation, migration, and invasion 
      were determined by Cell Counting Kit-8 (CCK-8) assays and Transwell assays with 
      or without Matrigel. The cell cycle was assessed by propidium iodide staining. 
      The protein level, mRNA level and half-life of PLK1 were detected by western 
      blotting and RT-qPCR. Results: In clinical patients, the expression of HuR was 
      significantly higher in lung cancer patients than in patients with benign lung 
      disease. RNA sequencing analysis of A549 HuR knockdown cells revealed that the 
      main function of HuR was related to ribonucleoprotein complex biogenesis. HuR was 
      found to regulate signaling pathways mainly related to the spliceosome, RNA 
      transport and the cell cycle. HuR KD suppressed the proliferation, migration and 
      invasion of A549 cells, indicating its promotive role in these processes. 
      Conclusion: These results demonstrate that HuR plays an important role in the 
      progression of lung cancer.
CI  - Copyright (c) 2022 Ye, Fu and Xiao.
FAU - Ye, Xiong
AU  - Ye X
AD  - School of Clinical Medicine, Shanghai University of Medicine & Health Sciences, 
      Shanghai, China.
FAU - Fu, Qiang
AU  - Fu Q
AD  - Department of Respiratory and Critical Care Medicine, Shanghai General Hospital, 
      Shanghai Jiaotong University, Shanghai, China.
FAU - Xiao, Hui
AU  - Xiao H
AD  - Department of Respiratory and Critical Care Medicine, Shanghai General Hospital, 
      Shanghai Jiaotong University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20220405
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC9016179
OTO - NOTNLM
OT  - RNA sequencing analysis
OT  - human antigen R
OT  - lung cancer
OT  - prognosis
OT  - proliferation
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/23 06:00
MHDA- 2022/04/23 06:01
PMCR- 2022/04/05
CRDT- 2022/04/22 06:39
PHST- 2021/11/11 00:00 [received]
PHST- 2022/03/09 00:00 [accepted]
PHST- 2022/04/22 06:39 [entrez]
PHST- 2022/04/23 06:00 [pubmed]
PHST- 2022/04/23 06:01 [medline]
PHST- 2022/04/05 00:00 [pmc-release]
AID - 813268 [pii]
AID - 10.3389/fgene.2022.813268 [doi]
PST - epublish
SO  - Front Genet. 2022 Apr 5;13:813268. doi: 10.3389/fgene.2022.813268. eCollection 
      2022.